Citius Oncology Appoints Independent Director Jonathan Peri

What Happened Citius Oncology, Inc. announced that its Board expanded to nine directors and appointed Jonathan Peri, Ph.D., J.D., as a Class I director effective August 10, 2026. Dr. Peri will serve until the company’s 2028 annual meeting of stockholders (or until his successor is elected). The Board has determined Dr. Peri is independent under SEC and Nasdaq rules, and the Board remains majority independent. Dr. Peri will be paid under the company’s independent director compensation program, which is currently under Board review.

Key Details

• Appointment effective: August 10, 2026; term through the 2028 annual meeting.
• Board size: expanded to nine directors; Board remains majority independent.
• Independence & compensation: Dr. Peri is independent per SEC/Nasdaq standards; director pay follows the company’s existing program (under review).
• Background: Dr. Peri (age 52) is President of Manor College since Oct 2015; Vice Chair of the Middle States Commission on Higher Education (appointed July 2026); former VP & General Counsel at Neumann University (2006–2015). Education: B.A. (Villanova), J.D. (Widener), doctorate in Organizational Leadership (Eastern University), MLE Certificate (Harvard).
• No related-party transactions: The filing discloses no transactions involving Dr. Peri that would require Item 404 disclosure. A press release about the appointment is attached as Exhibit 99.1.

Why It Matters Board additions and composition changes affect corporate governance and oversight. This appointment keeps Citius Oncology’s Board majority independent and adds a director with higher-education leadership and legal experience. For investors, the change is primarily a governance update (not a financial or operational event) but signals the company’s ongoing attention to board composition and independence.